<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149006</url>
  </required_header>
  <id_info>
    <org_study_id>271296-HMO-CTIL</org_study_id>
    <nct_id>NCT00149006</nct_id>
  </id_info>
  <brief_title>Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors</brief_title>
  <official_title>Tumor-Selective and Systemic Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With rIL-2 and Non-Myeloablative Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      The present protocol is designed to investigate the potential application of allogeneic&#xD;
      cell-mediated immunotherapy in metastatic solid tumors similarly to the well established&#xD;
      graft versus leukemia (GVL) effects in patients with hematologic malignancies.&#xD;
&#xD;
      Patients with metastatic solid tumors resistant to conventional modalities will be eligible&#xD;
      to participate in a treatment program based on the administration of non-myeloablative&#xD;
      immunotherapy (i.e. fludarabine, Cytoxan) followed by interferon injections; subsequently the&#xD;
      patients will be treated with mismatched alloreactive donor lymphocytes activated in vitro&#xD;
      and in vivo with rIL-2. The aim of this study is based on the recognition of foreign tumor&#xD;
      cell surface alloantigens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 1996</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study the feasibility, toxicity, and response rate of allogeneic cell therapy induced by selective intra-lesional and systemic administration of mismatched alloreactive lymphocytes in patients with metastatic cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study the feasibility, toxicity, and response to treatment with allogeneic mini-transplant using sibling donors in patients with metastatic cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cell therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Consenting patients (age &lt; 70) will be eligible for participation in the study involving&#xD;
        selective anti-tumor immunotherapy provided the following criteria are met:&#xD;
&#xD;
          -  Evidence of cancer not expected to be cured with conventional modalities&#xD;
&#xD;
          -  Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 and sarcomas. Adult&#xD;
             patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and selected&#xD;
             cases of ovarian cancer, gastrointestinal cancer, small-cell and non-small cell lung&#xD;
             cancer with non-bulky metastatic disease, and metastatic prostate cancer.&#xD;
&#xD;
          -  Patients with measurable disease evaluable for response with anticipated life&#xD;
             expectancy &gt; 3 months.&#xD;
&#xD;
          -  Patients must be &gt; 2 weeks off of anti-cancer or potentially immunosuppressive&#xD;
             treatment.&#xD;
&#xD;
          -  Adequate ambulatory performance status (Karnofsky &gt; 80%; ECOG 0-1) to enable&#xD;
             outpatient treatment.&#xD;
&#xD;
          -  Compliant and cooperative patients anticipated to be evaluable for response according&#xD;
             to the investigator's assessment.&#xD;
&#xD;
          -  HLA-compatible (fully matched or single locus mismatched) donor available for&#xD;
             allogeneic stem cell transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with bulky disease or patients with brain metastases resistant to&#xD;
             chemo-radiotherapy.&#xD;
&#xD;
          -  Patients with a significant history or current evidence of potentially severe&#xD;
             cardiovascular or lung disease, or other disease or clinical condition that may not&#xD;
             permit accomplishing the planned treatment or drawing conclusions.&#xD;
&#xD;
          -  Hepatic and/or renal failure.&#xD;
&#xD;
          -  Evidence of serious active infection requiring antibiotic therapy.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Contraindication for donation due to donor disease: HIV-1; hepatitis B surface antigen&#xD;
             (HBsAg) positivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shimon Slavin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reuven Or, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimon Slavin, MD</last_name>
    <phone>+972-2-6776561</phone>
    <email>slavin@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shimon Slavin, MD</last_name>
      <phone>+972-2-6776561</phone>
      <email>slavin@hadassah.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>March 13, 2007</last_update_submitted>
  <last_update_submitted_qc>March 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2007</last_update_posted>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>Mismatch allogeneic cell mediated immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

